

June 7, 2022

# BD Names Simon Campion as Medical Segment President

FRANKLIN LAKES, N.J., June 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as executive vice president (EVP) and president of the Medical segment for BD, effective July 1, 2022.



Campion, 51, will replace Alberto Mas who previously announced his intent to retire from BD. In this role, Campion will be responsible for the global strategic, operational and commercial performance of the Medical segment portfolio and will be accountable for delivering the segment's innovation agenda aligned to the BD 2025 strategy. Campion will also continue to lead the Interventional segment in the interim until a successor is named. He will report to Tom Polen, chairman, CEO and president of BD.

"Simon is a proven business leader with excellent strategic and operational skills and deep global experience," said Polen. "Since joining BD from the Bard acquisition, Simon has been integral in the integration and growth of the legacy Bard businesses across the Interventional segment and is well positioned to lead BD's largest segment."

Campion has served as EVP and president of the Interventional segment for BD since September 2018. Prior to that he was president of the BD Surgery business unit, where he integrated legacy Bard and BD product platforms into an integrated Surgery offering. Campion joined Bard in 2008 and held leadership roles in numerous Bard businesses in the U.S. and Europe. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific.

Campion holds a Ph.D. in Mechanical Engineering from the University of Limerick in Ireland and a Master of Business Administration from The Open University in the United Kingdom.

## About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative

technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit [bd.com](http://bd.com) or connect with us on LinkedIn at [www.linkedin.com/company/bd1/](http://www.linkedin.com/company/bd1/) and Twitter [@BDandCo](https://twitter.com/BDandCo).

**Contacts:**

Media:  
Troy Kirkpatrick  
VP, Public Relations  
858.617.2361  
[troy.kirkpatrick@bd.com](mailto:troy.kirkpatrick@bd.com)

Investors:  
Francesca DeMartino  
SVP, Head of Investor Relations  
201.847.5743  
[francesca.demartino@bd.com](mailto:francesca.demartino@bd.com)

View original content to download multimedia:<https://www.prnewswire.com/news-releases/bd-names-simon-campion-as-medical-segment-president-301562231.html>

SOURCE BD (Becton, Dickinson and Company)